Skip to main content

Lakatta, Edward

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #1,150
  • Sustained Excellence
  • Long-Funded
  • Top 10% Funded

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2008 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2023

Linked Award Amount
$3.9M
Full award amounts, FY2023
Award Records
21
Records listing this PI
Award-Linked Rank
#1,150
By linked amount among FY2023 PIs
Earliest Year Loaded
2008
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Lakatta, Edward. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2023 award records by amount

NIH award records listing Lakatta, Edward as a PI. Multi-PI records show the full award amount for context.

  • 1ZIAAG000869-16ZIAContact PI
    Marinobufagenin as a therapeutic target
    $1.3M
    award amount
  • 1ZIAAG000598-13ZIAContact PI
    Beat to beat Ca2+-dependent regulation of pacemaker cell rate and rhythm
    $416.6K
    award amount
  • 1ZIAAG000596-05ZIAContact PI
    The TGAC8 Mouse, the mouse that roars
    $396.5K
    award amount
  • 1ZIAAG000595-05ZIAContact PI
    Non-coding RNAs (ncRNAs) in Cardiovascular Aging
    $342.7K
    award amount
  • 1ZIAAG000594-03ZIAContact PI
    Effect of Long-term Photobiological Modulation Therapy on Aging
    $268.8K
    award amount
  • 1ZIAAG000262-16ZIAContact PI
    Decreased pacemaker activity in aged sinoatrial node
    $221.8K
    award amount
  • 1ZIAAG000230-02ZIAContact PI
    An echocardiographic study of age- and sex-dependent differences in cardiac function and morphometry in Non Human Primates
    $201.6K
    award amount
  • 1ZIAAG000299-04ZIAContact PI
    Extracellular vesicles coordinate intercellular signaling within the hearts pacemaker.
    $134.4K
    award amount
  • 1ZIAAG000798-14ZIAContact PI
    Tyrosine kinase receptors (VEGFR and EGFR) regulate normal automaticity of heart pacemaker, the sinoatrial node.
    $114.2K
    award amount
  • 1ZIAAG000232-16ZIAContact PI
    Coherent beat to beat variability of self-similar Ca2+ and surface membrane's signaling mechanisms determines the spontaneous action potential firing rate and rhythm of cardiac pacemaker cells
    $107.5K
    award amount

+11 more grants not shown.

Award organization

Organizations that administered FY2023 awards listing Lakatta, Edward as a PI.

FY2023 award administered by National Institute On Aging ().

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2008
    First NIH Award
    National Institute On Aging
  2. 2008
    $500K Cumulative Funding
  3. 2008
    $1M Cumulative Funding
  4. 2008
    $2M Cumulative Funding
  5. 2008
    Entered Top 50% Nationally
    Ranked #1356
  6. 2008
    Entered Top 25% Nationally
    Ranked #1356
  7. 2008
    Entered Top 10% Nationally
    Ranked #1356
  8. 2009
    $5M Cumulative Funding
  9. 2010
    $10M Cumulative Funding
  10. 2012
    Entered Top 5% Nationally
    Ranked #836
  11. 2013
    $25M Cumulative Funding
  12. 2017
    $50M Cumulative Funding